{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:49:14Z","timestamp":1781912954463,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die pr\u00e4diktive Biomarkertestung ist mittlerweile integraler Bestandteil der modernen Diagnostik und Therapieplanung bei \u00d6sophagus- und Magenkarzinomen. Sie besteht aktuell \u00fcberwiegend aus immunhistochemisch bestimmbaren Markern, wie der Expression des \u201eprogrammed death ligand\u00a01\u201c (PD-L1) bei (\u00f6sophagealen) Plattenepithelkarzinomen (angegeben mittels Tumor Proportion Score [TPS], Combined Positivity Score [CPS] und Tumor Area Proportion [TAP] Score), der HER2-Status (erg\u00e4nzt durch In-situ-Hybridisierung bei nichteindeutigen Ergebnissen), der Mismatch-repair-Status (fakultativ erg\u00e4nzt durch die molekularpathologische Bestimmung des Mikrosatellitenstatus) und seit Mitte des Jahrs 2024 auch die Expression von Claudin\u00a018.2 bei gastro\u00f6sophagealen Adenokarzinomen. Eine Erweiterung des Panels durch FGFR2b ist in naher Zukunft zu erwarten. Neben der den Qualit\u00e4tsrichtlinen entsprechenden technischen Durchf\u00fchrung der Untersuchungen ist auch die biologische Heterogenit\u00e4t vieler dieser Biomarker eine diagnostische und klinische Herausforderung. Dieser Artikel gibt einen \u00dcberblick \u00fcber die aktuelle Biomarkerdiagnostik bei Tumoren des oberen Gastrointestinaltrakts und setzt diese in einen entsprechenden onkologisch-therapeutischen Kontext.<\/jats:p>","DOI":"10.1007\/s00292-025-01506-x","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:37:20Z","timestamp":1765363040000},"page":"220-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarkerdiagnostik bei Karzinomen des oberen Gastrointestinaltrakts","Biomarker testing for carcinomas of the upper gastrointestinal tract"],"prefix":"10.1007","volume":"47","author":[{"given":"Drolaiz H. W.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Piringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"K\u00f6fler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-3609","authenticated-orcid":false,"given":"Rupert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang\u00a0YJ, Van Cutsem\u00a0E, Feyereislova\u00a0A et\u00a0al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase\u00a03, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"1506_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato\u00a0K, Cho\u00a0BC, Takahashi\u00a0M et\u00a0al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a\u00a0multicentre, randomised, open-label, phase\u00a03\u00a0trial. Lancet Oncol 20:1506\u20131517","journal-title":"Lancet Oncol"},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly\u00a0RJ, Ajani\u00a0JA, Kuzdzal\u00a0J et\u00a0al (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N\u00a0Engl J Med 384:1191\u20131203","journal-title":"N Engl J Med"},{"key":"1506_CR4","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu\u00a0MZ, Oh\u00a0DY, Kato\u00a0K et\u00a0al (2024) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase\u00a03\u00a0trial. BMJ 385:e78876","journal-title":"BMJ"},{"key":"1506_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara\u00a0K, Lordick\u00a0F, Bang\u00a0YJ et\u00a0al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a\u00a0multicentre, randomised, double-blind, phase\u00a03\u00a0trial. Lancet 401:1655\u20131668","journal-title":"Lancet"},{"key":"1506_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13304-022-01330-5","volume":"75","author":"G Businello","year":"2023","unstructured":"Businello\u00a0G, Angerilli\u00a0V, Lonardi\u00a0S et\u00a0al (2023) Current molecular biomarkers evaluation in gastric\/gastroesophageal junction adenocarcinoma: pathologist does matter. Updates Surg 75:291\u2013303","journal-title":"Updates Surg"},{"key":"1506_CR7","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.3390\/curroncol31120572","volume":"31","author":"C Brezden-Masley","year":"2024","unstructured":"Brezden-Masley\u00a0C, Fiset\u00a0PO, Cheung\u00a0CC et\u00a0al (2024) Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma. Curr Oncol 31:7770\u20137786","journal-title":"Curr Oncol"},{"key":"1506_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth\u00a0EC, Nilsson\u00a0M, Grabsch\u00a0HI et\u00a0al (2020) Gastric cancer. Lancet 396:635\u2013648","journal-title":"Lancet"},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff\u00a0J, Hanna\u00a0W, Bilous\u00a0M et\u00a0al (2012) HER2 testing in gastric cancer: a\u00a0practical approach. Mod Pathol 25:637\u2013650","journal-title":"Mod Pathol"},{"key":"1506_CR10","doi-asserted-by":"crossref","unstructured":"Lordick\u00a0F, Rha\u00a0SY, Muro\u00a0K et\u00a0al (2024) Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives. Cancers 16:3337","DOI":"10.3390\/cancers16193337"},{"key":"1506_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun\u00a0JM, Shen\u00a0L, Shah\u00a0MA et\u00a0al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0study. Lancet 398:759\u2013771","journal-title":"Lancet"},{"key":"1506_CR12","doi-asserted-by":"publisher","first-page":"16231","DOI":"10.1007\/s00432-023-05180-5","volume":"149","author":"GB Baretton","year":"2023","unstructured":"Baretton\u00a0GB, Lordick\u00a0F, Gaiser\u00a0T et\u00a0al (2023) Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J\u00a0Cancer Res Clin Oncol 149:16231\u201316238","journal-title":"J Cancer Res Clin Oncol"},{"key":"1506_CR13","doi-asserted-by":"publisher","first-page":"e2400230","DOI":"10.1200\/PO.24.00230","volume":"8","author":"SJ Klempner","year":"2024","unstructured":"Klempner\u00a0SJ, Cowden\u00a0ES, Cytryn\u00a0SL et\u00a0al (2024) PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28\u20118, 22C3, and SP263 Assays. JCO Precis Oncol 8:e2400230","journal-title":"JCO Precis Oncol"},{"key":"1506_CR14","doi-asserted-by":"crossref","unstructured":"Janjigian\u00a0YY, Al-Batran\u00a0SE, Wainberg\u00a0ZA et\u00a0al (2025) Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med 393:217-230","DOI":"10.1056\/NEJMoa2503701"},{"key":"1506_CR15","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.modpat.2025.100793","volume":"38","author":"M Moehler","year":"2025","unstructured":"Moehler\u00a0M, Yoon\u00a0HH, Wagner\u00a0DC et\u00a0al (2025) Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab. Mod Pathol 38:100793","journal-title":"Mod Pathol"},{"key":"1506_CR16","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-24-3473","volume":"31","author":"HS Walch","year":"2025","unstructured":"Walch\u00a0HS, Borpatragohain\u00a0R, Jee\u00a0J et\u00a0al (2025) Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer. Clin Cancer Res 31:1912\u20131921","journal-title":"Clin Cancer Res"},{"key":"1506_CR17","first-page":"61","volume":"44","author":"J R\u00fcschoff","year":"2023","unstructured":"R\u00fcschoff\u00a0J, Schildhaus\u00a0HU, R\u00fcschoff\u00a0JH et\u00a0al (2023) Testing for deficient mismatch repair and microsatellite instability: A\u00a0focused update. Pathol 44:61\u201370","journal-title":"Pathol (heidelb)"},{"key":"1506_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.humpath.2022.12.016","volume":"135","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi\u00a0H, Oishi\u00a0T, Sasaki\u00a0K et\u00a0al (2023) Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. Hum Pathol 135:54\u201364","journal-title":"Hum Pathol"},{"key":"1506_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara\u00a0K, Xu\u00a0RH, Ajani\u00a0JA et\u00a0al (2024) Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27:1058\u20131068","journal-title":"Gastric Cancer"},{"key":"1506_CR20","doi-asserted-by":"crossref","unstructured":"R\u00f6cken\u00a0C, H\u00f6hn\u00a0AK, Neumann\u00a0J et\u00a0al (2025) Concordance of laboratory assays for claudin 18.2 in gastric cancer tissue samples: independent proficiency testing and a descriptive non-interventional study. Virchows Arch (Jun 28; Online im Druck)","DOI":"10.1007\/s00428-025-04138-x"},{"key":"1506_CR21","doi-asserted-by":"publisher","first-page":"100589","DOI":"10.1016\/j.modpat.2024.100589","volume":"37","author":"M Fassan","year":"2024","unstructured":"Fassan\u00a0M, Kuwata\u00a0T, Matkowskyj\u00a0KA et\u00a0al (2024) Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A\u00a0Practical Approach. Mod Pathol 37:100589","journal-title":"Mod Pathol"},{"key":"1506_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu\u00a0J, Kato\u00a0K, Raymond\u00a0E et\u00a0al (2023) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a\u00a0global, randomised, placebo-controlled, phase\u00a03\u00a0study. Lancet Oncol 24:483\u2013495","journal-title":"Lancet Oncol"},{"key":"1506_CR23","doi-asserted-by":"publisher","first-page":"e257036","DOI":"10.6004\/jnccn.2025.7036","volume":"23","author":"J Yu","year":"2025","unstructured":"Yu\u00a0J, Mehta\u00a0R (2025) Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J\u00a0Natl Compr Canc Netw 23:e257036","journal-title":"J Natl Compr Canc Netw"},{"key":"1506_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000473881","volume":"85","author":"I Gullo","year":"2018","unstructured":"Gullo\u00a0I, Carneiro\u00a0F, Oliveira\u00a0C, Almeida\u00a0GM (2018) Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. Pathobiology 85:50\u201363","journal-title":"Pathobiology"},{"key":"1506_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/his.14059","volume":"76","author":"B Dislich","year":"2020","unstructured":"Dislich\u00a0B, Blaser\u00a0N, Berger\u00a0MD et\u00a0al (2020) Preservation of Epstein-Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer. Histopathology 76:740\u2013747","journal-title":"Histopathology"},{"key":"1506_CR26","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jtho.2019.06.019","volume":"14","author":"T Naito","year":"2019","unstructured":"Naito\u00a0T, Udagawa\u00a0H, Sato\u00a0J et\u00a0al (2019) A\u00a0Minimum Of 100 Tumor Cells in a\u00a0Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand\u00a01 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. J\u00a0Thorac Oncol 14:1818\u20131827","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1506_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","volume":"25","author":"JN Kather","year":"2019","unstructured":"Kather\u00a0JN, Pearson\u00a0AT, Halama\u00a0N et\u00a0al (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med 25(7):1054\u20131056","journal-title":"Nat Med"},{"key":"1506_CR28","doi-asserted-by":"publisher","first-page":"156068","DOI":"10.1016\/j.prp.2025.156068","volume":"272","author":"A Caputo","year":"2025","unstructured":"Caputo\u00a0A, Angerilli\u00a0V, Gambella\u00a0A et\u00a0al (2025) Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us? Pathol Res Pract 272:156068","journal-title":"Pathol Res Pract"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01506-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:58:13Z","timestamp":1777013893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01506-x","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"H.W.\u00a0Liu\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: AstraZeneca \u00d6sterreich GmbH (f\u00fcr einen anderen Artikel).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Pathologin, Klinisches Institut f\u00fcr Pathologie und Molekularpathologie, Kepler Universit\u00e4tsklinikum, Johannes Kepler Universit\u00e4t, Linz\u00a0| Mitgliedschaften: Pathologica Society of Great Britain & Ireland\u00a0| British Division der International Academy of Pathology\u00a0| European Society of Pathology.\n                      G.\u00a0Piringer\n                      : A.\u00a0Finanzielle Interessen: G.\u00a0Piringer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Universit\u00e4tsklinik f\u00fcr Onkologie, Kepler Universit\u00e4tsklinik Linz.\n                      S.\u00a0K\u00f6fler\n                      : A.\u00a0Finanzielle Interessen: S.\u00a0K\u00f6fler gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Universit\u00e4tsassistentin, Institut f\u00fcr Pathologie und Molekularpathologie, Johannes Kepler Universit\u00e4t Linz, Linz, \u00d6sterreich\u00a0| Mitgliedschaften: ESDIP\u00a0\u2013 European Society of Digital and Integrative Pathology.\n                      R.\u00a0Langer\n                      : A.\u00a0Finanzielle Interessen: Referentenhonorare Astellas, Roche, Onconovum, MSD.\u00a0\u2013 Ad-Board: MSD, Astra Zeneca.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Institutsleiter, Johannes Kepler Universit\u00e4t Linz\u00a0| Mitglied in \u00d6GPATH, SGPATH, DGP, IAP, Dt. Berufsverband, Dt. Hochschulverband, GIPS, OESO, IGCA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}